Will prostate # start or will the Baker brothers just continue to use this stock as a option/cash machine?
A bigger catalysts is coming with the medicare coverage ruling. A go and I suspect they finally let it go.
Rosie got it - there are simply no shares available no matter how hard they try. Good Luck
-Multiple studies presented at 2014 ASCO annual meeting reinforce unique, practice-changing value of Oncotype DXÂ® breast cancer test
Demonstrate importance of consistent results from multiple validation studies
Highlight substantial differences between multi-gene tests
Reinforce Genomic Healthâ#$%$™s commitment to improving the quality of treatment decisions for cancer patients
-GENEVA, Switzerland--(BUSINESS WIRE)-- Genomic Health, Inc.Â (Nasdaq: GHDX) announced results of three studies with the Oncotype DX breast cancer test at the recent 2014 American Society of Clinical OncologyÂ® (ASCOÂ®) Annual Meeting -
5% owner, 13D -Camber Capital Management, Institutional ownership - 3/30 had 750k now 1.7 M This is funny : % of Shares Held by All Insider and 5% Owners: 56%
% of Shares Held by Institutional & Mutual Fund Owners: 47%
% of Float Held by Institutional & Mutual Fund Owners: 107%
On June 13, 2014, Dean L. Schorno, Chief Financial Officer of Genomic Health, Inc. (the "Company"), notified the Company that he would be resigning from his position to pursue a chief financial officer opportunity with a privately held company. Mr. Schorno will remain available for consultation during a transition period.
(c) The Company's Board of Directors has appointed G. Bradley Cole, the Company's Chief Operating Officer, to serve in the additional positions of Chief Financial Officer and principal financial and accounting officer effective June 19, 2014. Mr. Cole, age 58, has served as the Company's Chief Operating Officer since January 2009, and also served as the Company's Chief Financial Officer from July 2004 until January 2011. Mr. Cole has no family relationships with any of the Company's directors or executive officers, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
The Company intends to conduct a search for a new Chief Financial Officer.
More positive data regarding prostate test
In the second quarter of 2014, we delivered record revenue with 17% growth in test volume and double-digit revenue growth. This impressive result was achieved by continuing to increase penetration of the U.S. invasive breast cancer market, as well as continued international adoption and reimbursement success. Further, we recently announced positive results from 2 additional large clinical validation studies in DCIS breast cancer and prostate cancer, both of which are large new markets representing nearly 200,000 patients in the U.S. alone each year.
we are pleased to report prostate test adoption accelerated at a strong pace resulting in a 54% increase in test volume compared with the first quarter of 2014. To date, approximately 900 urologists have ordered the Oncotype DX prostate cancer test, up 30% compared to the prior quarter, and more than half of these physicians have now ordered tests for multiple patients. We believe these results demonstrate physicians' recognition of the clinical value of Oncotype DX, the only prostate cancer test developed for low and intermediate risk patients, those most likely suitable for active surveillance.
We expect net loss in the third quarter to be greater than the second quarter due to increased R&D spending and continued planned investments in the U.S. DCIS, prostate cancer and international markets in order to position ourselves for rapid growth in all of these areas
today announced that Brad Cole, Chief Operating Officer and Chief Financial Officer, will present at the 34th Annual Canaccord Growth Conference in Boston on Wednesday, August 13 at 10:30 a.m. Eastern Time (ET).
Poster from Insmed board kvncmcdd ..INSM down almost 50 % in 6 weeks too bad
-Actually it will be closer to 300 million- )), as the revenues are starting to ramp up..- Why is the company controlled 95% by insiders,why so low a rev/sp??- Very few understand the genomic, except maybe Dr Pat Soon-Shiong- )...The Baker Brothers are using this stock as a cash machine bank until the moment is right=
Genomic Health just needs a powerful company to spread the word.Lets say Google decides to get into the genomic game because of the technology requires little medicine and just technology, or say a Pfizer ? Its amazing that so few have accepted lowered costs,and yes GHDX management has been very proactive abroad ( Thanks to Steve Burrill ). The tipping point will have to come from elsewhere. Good post,the US is deteriorating from within.Money politicians and lobbyists. Witness the 38 states with Rep gov who have have denied mil;lions healthcare because of politics...ok rant over.. GHDX is methodical in their technology Good Luck
Sicko from the Insmed message board that was on the wrong side of the trade.I was short. With that is a page and a half of erroueous information about me. Hit abuse or Ignore start with
Reply to Europe vs US by flatlander_60048 •Aug 12, 2014 12:52 PM post
Its the price you pay for a free board .freeaswhloes
Institutional numbers with a company like GHDX are full. THis quarter up slightly because most shares are held
For every share Fidelity share was swallowed up by CAMBER CAPITAL MANAGEMENT LLC and more.
The companys largest holder by far the Bakers increased slightly . Go back to the INSM board clown
Unfortunately the latest spam is another juvenile from the Insmed board."arikaycerocks". We know this is a young girl named Evelyn from Britain who writes stuff like INSM $ 600 soon!. Insmed is a loser bio that the FDA just pushed back almost 4 years and of course someone who invested correctly(short) is the bad guy - just ignore the child-
****arikaycerocks post is SPAM . Ignore . The spam on this board comes from this idiot from the Insmed mb that has lost a ton.and since I was a short and made a ton, this clown spams this board
nine studies of Oncotype DXÂ® in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, September 26 - 30.
- Included in the program is the first presentation of strongly positive results from an additional large independent clinical validation study of the Oncotype DX prostate cancer test, conducted in collaboration with the Center for Prostate Disease Research, Rockville, Md.-
- This new study demonstrates the test's ability to predict a rise in prostate-specific antigen (PSA) following surgery (biochemical recurrence) and reconfirms Oncotype DX as a predictor of adverse pathology from the biopsy, as previously demonstrated in a published validation study performed by the University of California-
today announced that PharmacoEconomics published positive results from a health economic analysis -suggesting that use of the OncotypeA DX colon cancer test may result in a significant reduction in direct -medical costs and improve patient quality of life by helping them avoid side effects of unnecessary treatment
-"By providing quantitative information which has not been available with conventional measures, as -demonstrated in this analysis, the Oncotype DX colon cancer test is likely to lead to both savings in direct -medical costs and improved patient well-being," said Steven Alberts, M.D., chair, division of Medical Oncology -at the Mayo Clinic, Rochester, Minn.
-The analysis of 141 patients from 17 sites in the Mayo Clinic Cancer Research Consortium demonstrated the v-alue of using the Oncotype DX test to identify stage II colon cancer patients with low risk of recurrence, who m-ay consider forgoing a chemotherapy regimen. After physicians received the Recurrence Score results, their re-commendations for adjuvant chemotherapy in patients with low risk of recurrence decreased by 22 percent, wh-ich resulted in direct medical care cost savings of approximately $1,000 per patient. This is the first health eco-nomic study of the Oncotype DX colon cancer test conducted in clinical practice. A previous, separate mod-eling study showing that the use of the Oncotype DX test in stage II colon cancer patients may lead to healt-h care cost savings while improving clinical outcomes was published in 2012 by Value of Health.
"-This publication highlights the important role of the Oncotype DX colon cancer test in delivering personalized m-edicine to the modern paradigm for cancer care," said George Kim, M.D., gastrointestinal oncologist, 21st Ce-ntury Oncology, Jacksonville, Fla. "By enabling a more